Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy;Erhöhte Haut- und Schleimhauttoxizität bei Kombination von Vemurafenib plus Strahlentherapie

Strahlentherapie und Onkologie

Volumn 190, Issue 12, 2014, Pages 1169-1172

  Merten, Ricarda ^a   Hecht, Markus ^a   Haderlein, Marlen ^a   Distel, Luitpold ^a   Fietkau, Rainer ^a   Heinzerling, Lucie ^a   Semrau, Sabine ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

BRAF; Radiation; Radiosensitization; Radiotherapy; Vemurafenib

Indexed keywords

VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BACKACHE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ERYTHEMA; ESOPHAGITIS; HUMAN; HYPERPIGMENTATION; LIMB WEAKNESS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PARENTERAL NUTRITION; PNEUMONIA; POOR GENERAL CONDITION; SKIN MANIFESTATION; SKIN TOXICITY; SPINE FRACTURE; WEIGHT REDUCTION; CHEMORADIOTHERAPY; MUCOSITIS; PROCEDURES; RADIODERMATITIS; RADIOGRAPHY; SECONDARY; SPINAL CORD TUMOR; TREATMENT OUTCOME;

ADULT; CHEMORADIOTHERAPY; ESOPHAGITIS; HUMANS; INDOLES; MALE; MUCOSITIS; PALLIATIVE CARE; RADIODERMATITIS; SPINAL NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84911805773     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0698-x     Document Type: Article

References (16)

1. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
2. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al (1999) Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 44:607–618
3. Freundt K, Meyners T, Bajrovic A et al (2010) Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. Strahlenther Onkol 186:218–223
4. Wachenfeld I, Sanner G, Bottcher HD, Kollath J (1996) [The remineralization of the vertebral metastases of breast carcinoma after radiotherapy]. Strahlenther Onkol 172:332–341
5. Coelho SG, Miller SA, Zmudzka BZ, Beer JZ (2006) Quantification of UV-induced erythema and pigmentation using computer-assisted digital image evaluation. Photochem Photobiol 82:651–655
6. Distel LV, Neubauer S, Keller U, Sprung CN, Sauer R, Grabenbauer GG (2006) Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol 81:257–263
7. Boussemart L, Boivin C, Claveau J et al (2013) Vemurafenib and Radiosensitization. Jama Dermatology 149:855–857
8. Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M (2014) Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J Eur Acad Dermatol Venereol (in press)
9. Boussemart L, Routier E, Mateus C et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691–1697
10. Anker CJ, Ribas A, Grossmann AH et al (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283–e287
11. Reigneau M, Granel-Brocard F, Geoffrois L et al (2013) Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis? Eur J Dermatol 23:544–555
12. Schulze B, Meissner M, Wolter M, Rodel C, Weiss C (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 190:229–32
13. Narayana A, Mathew M, Tam M et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411–416
14. Friberg S, Mattson S (1997) On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65:284–297
15. Dasgupta T, Haas-Kogan DA, Yang X et al (2013) Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs 31:1136–1141
16. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394–399